At what stage are we in active surveillance for localized prostate cancer? Our clinical experience
- 27 February 2023
- journal article
- research article
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 18 (1) , 8-15
Abstract
Objective: Prostate cancer (PCa) is the most common malignancy in men and early diagnosis can be made by screening. Active surveillance (AS) is one of the options for disease management in patients with low-risk prostate cancer (LRPC). In this study, we aimed to evaluate our clinical experience in AS for prostate cancer. Material and Methods: Data from 1650 patients who were diagnosed with PCa in the period between January 2014 and December 2019, were retrospectively reviewed. Inclusion criteria were defined as being under 75 years of age and having a 10-year life expectancy, being at clinical stages of T1-T2a, having a PSA level of <10 ng/dl, having positive biopsy cores of ≤2, and having a Gleason score of ≤6 as the result of the pathological examination of the biopsy specimen. Patients not meeting any of the inclusion criteria were excluded from the study. Results: After the inclusion and exclusion criteria, 176 patients agreed to undergo AS and were included in the study. The mean follow-up duration was 25.2 ± 13 months. A total of 57 patients (32.3%) left the AS program to undergo definitive treatment. Definitive treatment was radical prostatectomy in 38 (65.5%) patients, radiotherapy in 18 (31%) patients, and hormonotherapy in one (1.7%) patient. Conclusion: AS is a method that helps avoid the complications of definitive treatment in LRPC patients. It can be used as an alternative option to definitive treatment in the management of these patients. However, it should not be forgotten that pathological upgrades may occur in 30% of AS patients, indicating the need for definitive treatment. Keywords: prostate cancer, active surveillance, low-risk prostate cancerKeywords
This publication has 28 references indexed in Scilit:
- Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?European Urology, 2015
- Trends in Management for Patients With Localized Prostate Cancer, 1990-2013JAMA, 2015
- Medium-term Outcomes of Active Surveillance for Localised Prostate CancerEuropean Urology, 2013
- ‘It's not like you just had a heart attack’: decision‐making about active surveillance by men with localized prostate cancerPsycho-Oncology, 2013
- Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS StudyEuropean Urology, 2013
- Outcome Following Active Surveillance of Men with Screen-detected Prostate Cancer. Results from the Göteborg Randomised Population-based Prostate Cancer Screening TrialEuropean Urology, 2013
- Active Surveillance for Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2012
- Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational StudyEuropean Urology, 2012
- Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary GradesEuropean Urology, 2012
- Careful Selection and Close Monitoring of Low-Risk Prostate Cancer Patients on Active Surveillance Minimizes the Need for TreatmentEuropean Urology, 2010